Effective January 24, 2022, the FDA updated the Emergency Use Authorization (EUA) fact sheets for two COVID-19 monoclonal antibody treatments: bamlanivimab plus etesevimab (Eli Lilly) and casirivimab plus imdevimab (Regeneron, also known as REGEN-COV). Neither of these treatments are authorized for use anywhere in the U.S. due to their ineffectiveness against the dominant Omicron variant. Sites are directed to immediately stop administering these therapeutics as they do not retain EUA.

Ph: (443) 281-9157

Fax: (410) 582-8728

801 Landmark Dr.
Glen Burnie, MD 21061
Contact Us

Mon-Fri: 8:30AM-6:30PM

Sat: 9:00AM-2:00PM
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping